Drug Profile
Taragarestrant - InventisBio
Alternative Names: D 0502Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator InventisBio
- Class Acrylates; Antineoplastics; Hexanes; Methylamines; Pentanoic acids; Phenols; Pyridones; Small molecules
- Mechanism of Action Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HER2 negative breast cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in HER2-negative-breast-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO, Tablet)
- 28 Feb 2024 No recent reports of development identified for phase-I development in HER2-negative-breast-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Tablet)
- 28 Feb 2024 No recent reports of development identified for phase-I development in HER2-negative-breast-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in China (PO, Tablet)